Angiotensinogen Exerts Effects Independent of Angiotensin II

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 2, 2016, Pages 256-265

  Lu, Hong ^a   Wu, Congqing ^a   Howatt, Deborah A ^a   Balakrishnan, Anju ^a   Moorleghen, Jessica J ^a   Chen, Xiaofeng ^a   Zhao, Mingming ^a   Graham, Mark J ^b   Mullick, Adam E ^b   Crooke, Rosanne M ^b   Feldman, David L ^c   Cassis, Lisa A ^a   Kooi, Craig W Vander ^a   Daugherty, Alan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

angiotensinogen; atherosclerosis; blood pressure; liver steatosis; obesity

Indexed keywords

ADIPONECTIN; ALISKIREN; ANGIOPOIETIN 1; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; NEOMYCIN; OSTEONECTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RENIN; SATURATED FATTY ACID; THROMBOSPONDIN 1; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 1; VASCULOTROPIN A; AGT PROTEIN, MOUSE; AMIDE; FUMARIC ACID DERIVATIVE; PROTEIN BINDING;

ADULT; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BETA SHEET; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAT INTAKE; FATTY LIVER; FEMALE; GENETIC ENGINEERING; HYPERCHOLESTEROLEMIA; INTRON; LOXP SITE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PHENOTYPE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; C57BL MOUSE; CONSERVED SEQUENCE; DEFICIENCY; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GENOTYPE; HYPERTENSION; KNOCKOUT MOUSE; LIPID DIET; LIVER; LIVER CELL; MALE; METABOLISM; MOLECULAR MODEL; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR;

AMIDES; AMINO ACID SEQUENCE; ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; CONSERVED SEQUENCE; DEPENDOVIRUS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; FUMARATES; GENETIC VECTORS; GENOTYPE; HEPATOCYTES; HYPERTENSION; LIVER; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, LDL; RENIN; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSDUCTION, GENETIC; WEIGHT GAIN;

EID: 84955696851     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306740     Document Type: Article

References (48)

1. Hatae T, Takimoto E, Murakami K, Fukamizu A, Comparative studies on species-specific reactivity between renin and angiotensinogen. Mol Cell Biochem 1994 131 43 47
2. Célérier J, Cruz A, Lamandé N, Gasc JM, Corvol P, Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 2002 39 224 228
3. Corvol P, Lamandé N, Cruz A, Celerier J, Gasc JM, Inhibition of angiogenesis: a new function for angiotensinogen and des(angiotensin I)angiotensinogen. Curr Hypertens Rep 2003 5 149 154
4. Bouquet C, Lamandé N, Brand M, Gasc JM, Jullienne B, Faure G, Griscelli F, Opolon P, Connault E, Perricaudet M, Corvol P, Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol Ther 2006 14 175 182. doi: 10.1016/j.ymthe.2006.01.017.
5. Brand M, Lamandé N, Sigmund CD, Larger E, Corvol P, Gasc JM, Angiotensinogen modulates renal vasculature growth. Hypertension 2006 47 1067 1074. doi: 10.1161/01.HYP.0000221065.05670.23.
6. Brand M, Lamandé N, Larger E, Corvol P, Gasc JM, Angiotensinogen impairs angiogenesis in the chick chorioallantoic membrane. J Mol Med (Berl) 2007 85 451 460. doi: 10.1007/s00109-006-0141-6.
7. Vincent F, Bonnin P, Clemessy M, Contrerès JO, Lamandé N, Gasc JM, Vilar J, Hainaud P, Tobelem G, Corvol P, Dupuy E, Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res 2009 69 2853 2860. doi: 10.1158/0008-5472.CAN-08-2484.
8. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A, Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008 118 984 993. doi: 10.1172/JCI32970.
9. Weiss D, Kools JJ, Taylor WR, Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001 103 448 454
10. Lu H, Cassis LA, Daugherty A, Atherosclerosis and arterial blood pressure in mice. Curr Drug Targets 2007 8 1181 1189
11. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA, Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004 110 3849 3857. doi: 10.1161/01.CIR.0000150540.54220.C4.
12. Lu H, Balakrishnan A, Howatt DA, Wu C, Charnigo R, Liau G, Cassis LA, Daugherty A, Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Br J Pharmacol 2012 165 2000 2008. doi: 10.1111/j.1476-5381.2011.01712.x.
13. Daugherty A, Manning MW, Cassis LA, Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000 105 1605 1612. doi: 10.1172/JCI7818.
14. Smithies O, Kim HS, Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci USA 1994 91 3612 3615
15. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, Fukamizu A, Murakami K, Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994 269 31334 31337
16. Wu C, Xu Y, Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Vander Kooi CW, Cassis LA, Wang JA, Daugherty A, Cys18-Cys137 disulfide bond in mouse angiotensinogen does not affect AngII-dependent functions in vivo. Hypertension 2015 65 800 805. doi: 10.1161/HYPERTENSIONAHA.115.05166.
17. Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, Daugherty A, Cassis LA, Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension 2012 60 1524 1530. doi: 10.1161/HYPERTENSIONAHA.112.192690.
18. Yiannikouris F, Karounos M, Charnigo R, English VL, Rateri DL, Daugherty A, Cassis LA, Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol 2012 302 R244 R251. doi: 10.1152/ajpregu.00323.2011.
19. Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, Fukamizu A, Negrel R, Ailhaud G, Teboul M, Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001 142 5220 5225. doi: 10.1210/endo.142.12.8556.
20. Wu C, Lu H, Cassis LA, Daugherty A, Molecular and pathophysiological features of angiotensinogen: a mini review. N Am J Med Sci (Boston) 2011 4 183 190
21. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T, Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999 17 537 545
22. Dutta P, Courties G, Wei Y, Myocardial infarction accelerates atherosclerosis. Nature 2012 487 325 329. doi: 10.1038/nature11260.
23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr, Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003 112 1796 1808. doi: 10.1172/JCI19246.
24. Chen X, Lu H, Zhao M, Tashiro K, Cassis LA, Daugherty A, Contributions of leukocyte angiotensin-converting enzyme to development of atherosclerosis. Arterioscler Thromb Vasc Biol 2013 33 2075 2080. doi: 10.1161/ATVBAHA.113.301777.
25. Tanaka T, Ohkubo H, Nakanishi S, Common structural organization of the angiotensinogen and the alpha 1-antitrypsin genes. 1984 259 8063 8065
26. Zhou A, Carrell RW, Murphy MP, Wei Z, Yan Y, Stanley PL, Stein PE, Broughton Pipkin F, Read RJ, A redox switch in angiotensinogen modulates angiotensin release. Nature 2010 468 108 111. doi: 10.1038/nature09505.
27. Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma JT, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, Saltiel AR, The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 2009 138 961 975. doi: 10.1016/j.cell.2009.06.046.
28. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA, Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007 292 E1280 E1287. doi: 10.1152/ajpendo.00277.2006.
29. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M, Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001 15 2727 2729. doi: 10.1096/fj.01-0457fje.
30. Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, Bartness TJ, Kim HS, Harp JB, Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 2007 6 506 512. doi: 10.1016/j.cmet.2007.10.011.
31. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS, Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 2008 105 6531 6536. doi: 10.1073/pnas.0802690105.
32. Oliverio MI, Kim HS, Ito M, Le T, Audoly L, Best CF, Hiller S, Kluckman K, Maeda N, Smithies O, Coffman TM, Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci USA 1998 95 15496 15501
33. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T, Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995 377 748 750. doi: 10.1038/377748a0.
34. Taniguchi K, Sugiyama F, Kakinuma Y, Uehara S, Nishijho N, Tanimoto K, Murakami K, Fukamizu A, Yagami KI, Pathologic characterization of hypotensive C57BL/6J-agt: angiotensinogen-deficient C57BL/6J mice. Int J Mol Med 1998 1 583 587
35. Yanai K, Saito T, Kakinuma Y, Kon Y, Hirota K, Taniguchi-Yanai K, Nishijo N, Shigematsu Y, Horiguchi H, Kasuya Y, Sugiyama F, Yagami Ki, Murakami K, Fukamizu A, Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J Biol Chem 2000 275 5 8
36. Takahashi N, Lopez ML, Cowhig JE Jr, Taylor MA, Hatada T, Riggs E, Lee G, Gomez RA, Kim HS, Smithies O, Ren1c homozygous null mice are hypotensive and polyuric, but heterozygotes are indistinguishable from wild-type. J Am Soc Nephrol 2005 16 125 132. doi: 10.1681/ASN.2004060490.
37. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O'Brien DA, Smithies O, Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995 375 146 148. doi: 10.1038/375146a0.
38. Stucchi P, Cano V, Ruiz-Gayo M, Fernández-Alfonso MS, Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 2009 158 771 778. doi: 10.1111/j.1476-5381.2009.00355.x.
39. Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M, Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 2009 98 192 197. doi: 10.1016/j.physbeh.2009.05.009.
40. Frantz ED, Penna-de-Carvalho A, Batista Tde M, Aguila MB, Mandarim-de-Lacerda CA, Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice. Metab Syndr Relat Disord 2014 12 191 201. doi: 10.1089/met.2013.0129.
41. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB, Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004 53 336 346
42. Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, Honda K, Suzuki Y, Kawabe Y, Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 2013 170 519 531. doi: 10.1111/bph.12269.
43. Fujisaka S, Usui I, Kanatani Y, Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology 2011 152 1789 1799. doi: 10.1210/en.2010-1312.
44. Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA, Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 2010 119 239 250. doi: 10.1042/CS20100061.
45. Ye Y, Qian J, Castillo AC, Perez-Polo JR, Birnbaum Y, Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther 2011 25 505 515. doi: 10.1007/s10557-011-6339-z.
46. Grothusen C, Bley S, Selle T, Luchtefeld M, Grote K, Tietge UJ, Drexler H, Schieffer B, Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005 182 57 69. doi: 10.1016/j.atherosclerosis.2005.01.045.
47. Thatcher SE, Zhang X, Howatt DA, Lu H, Gurley SB, Daugherty A, Cassis LA, Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/-mice. Arterioscler Thromb Vasc Biol 2011 31 758 765. doi: 10.1161/ATVBAHA.110.221614.
48. Postic C, Magnuson MA, DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 2000 26 149 150